Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01023672
Other study ID # 09-003438
Secondary ID R01AG015866P50AG
Status Completed
Phase Phase 4
First received December 1, 2009
Last updated June 24, 2013
Start date November 2009
Est. completion date March 2012

Study information

Verified date June 2013
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This research study is to examine the effects of the study medication Armodafinil in patients with dementia with Lewy bodies (DLB).

DLB is associated with memory and other thinking problems, excessive daytime sleepiness, hallucinations, delusions, apathy, and reduced quality of life.

One type of medication that could potentially improve daytime sleepiness, memory and thinking skills, hallucinations, delusions, apathy, and quality of life is known as a wake-promoting medication. Armodafinil is a wake-promoting medication that has been developed for treatment of patients with narcolepsy, sleep apnea, and other disorders which cause excessive daytime sleepiness.

The drug used in this study is considered investigational, which means it has either not been approved by the Food and Drug Administration (FDA) for routine clinical use or for the use described in this study. However the FDA has allowed the use of this drug/device in this research study.

In this study, patients with DLB will receive daily oral Armodafinil tablets, and their response to treatment will be assessed over 12 weeks. This study does not involve any placebo medication, so all patients will receive Armodafinil treatment.


Description:

In patients with DLB, the following aims/objectives will be addressed by comparing data on key measures at baseline and at 4 and 12 weeks of therapy:

Primary Aims - to test the hypotheses that armodafinil therapy at 150-250 mg every morning:

- will result in improvement in excessive daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS) and Maintenance of Wakefulness Test (MWT) (Aim 1A)

- will result in improvement in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) (Aim 1B)

- will result in improvement in the Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change (ADCS-CGIC) (Aim 1C)

- will be well-tolerated with no significant side-effects present (Aim 1D)

Secondary Aims - to test the hypotheses that armodafinil therapy at 150-250 mg every morning will result in improvement in:

- cognition as measured by the Mini-Mental State Examination (MMSE) and other focused neuropsychological tests (Aim 2A)

- neuropsychiatric morbidity, particularly apathy, depression, visual hallucinations, and delusions, as measured by the Neuropsychiatric Inventory (NPI) (Aim 2B)

- functional status as measured by the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) (Aim 2C)

- patient and caregiver quality of life (QOL) as measured by the linear analog scale (LASA) (Aim 2D)


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date March 2012
Est. primary completion date March 2012
Accepts healthy volunteers No
Gender Both
Age group 50 Years to 90 Years
Eligibility Inclusion Criteria:

- Diagnosis of clinically possible or probable DLB using established criteria

- Age 50-90 inclusive

- Epworth Sleepiness Scale score of 8 or greater

- MMSE score between 10 and 26 inclusive

- No active medical disorder that could preclude participation in a drug treatment trial over a 12 week protocol

- Stable medication regimen over previous four weeks

- Absence of psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness

- Absence of clinically significant primary sleep-related breathing disorder causing sleepiness as demonstrated by polysomnography (PSG) [ie, no significant upper airway resistance syndrome (UARS), obstructive sleep apnea (OSA), nor central sleep apnea (CSA) as reflected by a combined respiratory disturbance index (RDI) <15] OR adequate documentation of efficacy of treatment for UARS, OSA, and CSA

- Caregiver that is with the patient at least 4 hours/day for at least 5 days per week

- Patient and caregiver willing and able to participate in all study-related procedures

- Patient is capable of giving informed consent, or if appropriate, has caregiver capable of giving consent on the subject's behalf.

Exclusion Criteria:

- Does not fulfill criteria for clinically possible or probable DLB

- Age <50 or >90

- Women with intact uterus and not post-menopausal unless pregnancy test performed at screening is negative

- Epworth Sleepiness Scale score less than 8

- MMSE score <10 or >26

- Active medical disorder that could preclude participation in a drug treatment trial over a 52 week protocol, such as:

- Hypertension with BP readings exceeding 150 mm Hg systolic and 90 mm Hg diastolic

- Hypersensitivity to modafinil, armodafinil, or any other conventional stimulants

- Myocardial infarction or cerebral infarct over preceding year, stable or unstable angina, known symptomatic coronary artery disease

- History of left ventricular hypertrophy or mitral valve prolapse

- History of chronic or paroxysmal atrial fibrillation, chronic or paroxysmal atrial flutter, ventricular fibrillation, or ventricular tachycardia

- History of cancer over preceding 1 year (excluding squamous or basal cell carcinoma of the skin)

- History of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS)

- Pulmonary disease requiring oral or inhalatory medications

- Any other medical disorder considered by the study physicians as inappropriate for any wake-promoting medication

- Medication regimen has not been stable over preceding four weeks

- Concurrent use of lamotrigine or oxcarbazepine

- Presence of over-the-counter and prescription psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness, such as:

- Clonazepam > 1 mg/night

- Seroquel > 100 mg/night

- Zyprexa > 10 mg/night

- Presence of another clinically-significant primary sleep disorder (eg, UARS, OSA, CSA) that is not being treated

- Clinically significant abnormalities on screening ECG or laboratory tests

- Patient or caregiver unwilling or unable to participate in all study-related procedures

- Caregiver is not with patient at least 4 hours/day for at least 5 days/week

- Patient or caregiver unwilling or unable to provide informed consent

- CT or MRI evidence of a clinically significant structural lesion that could account for the participants dementia

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Armodafinil
150-250 mg armodafinil by mouth daily

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (3)

Lead Sponsor Collaborator
Mayo Clinic Cephalon, National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Initial Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) The MWT measures the subject's ability to stay awake while sitting quietly in a chair. The test has 4 parts, each lasting 40 minutes if the subject is able to remain awake that long each time, and the parts are spaced apart in 2 hour intervals through the day.
The subject is placed in a dim room, with the only source of light slightly behind the subject's head and out of his/her field of vision, and back and neck supported. During this time the subject is monitored with the same measures that are used in a standard overnight sleep study called a polysomnogram. The sleep latency, or time it takes the subject to fall asleep, will be recorded.
In healthy people, the time it takes to fall asleep may be approximately 30 minutes on the test. More than 97% of people will take eight minutes or longer to fall asleep. Therefore, sleep latency that is less than eight minutes is considered to be abnormal.
baseline, 12 weeks Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03996460 - K0706 for Patients Diagnosed With Dementia With Lewy Bodies Phase 2
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Recruiting NCT02194816 - Modifiable Variables in Parkinsonism (MVP)
Active, not recruiting NCT01208675 - The Swedish BioFINDER Study
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Recruiting NCT03672448 - The China Longitudinal Aging Study of Cognitive Impairment
Completed NCT01340001 - Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies N/A
Not yet recruiting NCT04760860 - Terazosin for Dementia With Lewy Bodies Phase 1/Phase 2
Terminated NCT02928445 - Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension Phase 2/Phase 3
Completed NCT02910102 - Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia Phase 2
Terminated NCT02871427 - Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Phase 2
Completed NCT05188105 - Alpha tACS in Dementia With Lewy Bodies N/A
Active, not recruiting NCT04167813 - Trial of Ondansetron as a Parkinson's HAllucinations Treatment Phase 2
Enrolling by invitation NCT04954183 - Development of an EEG Diagnostic for Alzheimer's Disease
Recruiting NCT05326750 - Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases N/A
Completed NCT03907748 - Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia N/A
Completed NCT04649164 - Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia N/A
Recruiting NCT03924414 - Trial of Parkinson's And Zoledronic Acid Phase 4
Completed NCT05885620 - SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia N/A
Not yet recruiting NCT04555629 - Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK) N/A